SLC5A2 and type 2 diabetes mellitus: Recently, GLP-1 receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are considered as the glucose-lowering drugs that have moderated benefits in reducing cardiovascular risk among T2DM patients [10].